Eli Lilly: 'Strong Buy' Raised Revenue Guidance By $2 Billion For 2026 And Label Expansions

🇺🇸 Seeking Alpha (US) —

AI Summary

Eli Lilly raised its revenue guidance by $2 billion for 2026, attributing this increase to planned label expansions of its products. The pharmaceutical company is regarded as a strong buy in the current market due to these positive projections.

Markets Deals Health Eli Lilly revenue guidance label expansions pharmaceuticals strong buy

Read original source →